Mereo BioPharma Group (MREO) versus Its Peers Head-To-Head Review

Mereo BioPharma Group (NASDAQ: MREO) is one of 618 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Mereo BioPharma Group to related businesses based on the strength of its dividends, earnings, institutional ownership, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

14.2% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 45.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.5% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Mereo BioPharma Group and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mereo BioPharma Group N/A -$44.49 million -1.18
Mereo BioPharma Group Competitors $2.12 billion $260.75 million 0.65

Mereo BioPharma Group’s rivals have higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Mereo BioPharma Group and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mereo BioPharma Group N/A N/A N/A
Mereo BioPharma Group Competitors -3,409.24% -244.96% -33.16%

Analyst Ratings

This is a summary of recent recommendations for Mereo BioPharma Group and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mereo BioPharma Group 0 0 1 0 3.00
Mereo BioPharma Group Competitors 6719 18643 36014 1437 2.51

As a group, “Pharmaceutical preparations” companies have a potential upside of 36.44%. Given Mereo BioPharma Group’s rivals higher probable upside, analysts clearly believe Mereo BioPharma Group has less favorable growth aspects than its rivals.


Mereo BioPharma Group rivals beat Mereo BioPharma Group on 7 of the 12 factors compared.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with's FREE daily email newsletter.